Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-212 Monotherapy and Combined With Toripalimab in Solid Tumors
NCT05579275Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2023
- Primary completion
- Apr 2026
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of JCXH-212 in malignant solid tumor (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Dose-Limiting Toxicity at 21 days and Primary Efficacy Indicators. Started Feb 2023; status: recruiting.
02
Drugs
JCXH-212
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05579275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579275.